A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A

Abstract

AbstractIntroductionThe safety and efficacy of the extended half‐life factor VIII (FVIII) product damoctocog alfa pegol (BAY 94‐9027, Jivi®) has been demonstrated in the PROTECT VIII Kids study (NCT01775618), where male previously‐treated patients (PTPs) aged <12 years old with severe haemophilia A and ≥ 50 exposure days (EDs) were treated prophylactically. The PROTECT VIII Kids extension study assessed the long‐term safety and efficacy of damoctocog alfa pegol in the same population.AimTo evaluate the long‐term impact of damoctocog alfa pegol in a post hoc subgroup analysis of adolescent patients in the PROTECT VIII Kids study and its extension from 12th birthday onwards.MethodsThe current analysis included PTPs aged ≥12 years old, who remained in the extension for ≥6 months following their 12th birthday. The observation period was defined as the time from 12th birthday to the end of the extension period; all data from this birthday were included whether in the main study or extension phase. The main efficacy variable was annualised bleeding rate (ABR) and the main safety variable was the frequency of inhibitor development.ResultsThis subgroup analysis comprised 25 patients. Median observation time after 12th birthday was 3.2 years. Median total/joint/spontaneous ABRs in the observation period were 1.7/0.7/0.3, respectively. Safety findings were consistent with those reported for the overall study population; no confirmed FVIII inhibitors or anti‐drug antibodies were reported.ConclusionsDamoctocog alfa pegol is efficacious with a favourable safety profile in adolescents with haemophilia A, supporting its long‐term use in children and adolescents.